Compare AstraZeneca plc (AZN) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Amplify Transformational Data Sharing ETF — how do they compare? AstraZeneca plc trades at $158.74 (market cap $248.14B), while Amplify Transformational Data Sharing ETF trades at $59.99. The key difference: AstraZeneca plc pays a 2.01% dividend while Amplify Transformational Data Sharing ETF pays none, and Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | BLOK | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $74.10 |
52-Week Low | $147.06 | $47.36 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
BLOK trades at $60.00, up 1.56% today, but faces bearish technical signals with 14 sell indicators versus 2 buy signals. The stock shows neutral momentum oscillators while moving averages signal downward pressure. Recent institutional activity shows Dynamic Advisor Solutions reduced its position by 81.1% in Q2 2026. The ETF focuses on transformational data sharing companies with exposure to AI infrastructure and blockchain economy participants.
The outlook remains cautious given bearish technical indicators and institutional selling. Investment opportunity exists in the ETF's diversified exposure to data sharing and AI infrastructure growth, but risks include sector volatility and competitive ETF pressure. The dividend of $0.08 scheduled for June 2026 provides minor income support amid uncertain market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
